PMVP Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
20.1M
+6.3%
18.9M
-0.7%
19.0M
-1.2%
19.2M
-14.6%
22.5M
R&D
16.1M
+9.5%
14.7M
-4.3%
15.3M
-3.1%
15.8M
-13.1%
18.2M
SG&A
4.0M
-4.9%
4.2M
+14.0%
3.7M
+8.0%
3.4M
-20.8%
4.3M
Operating Income
-20063000
-6.3%
-18881000
+0.7%
-19019000
+1.2%
-19242000
+14.6%
-22522000
EBITDA
-20040000
-6.3%
-18857000
+0.7%
-18985000
+1.2%
-19209000
+14.6%
-22491000
Net Income
-34372000
-90.0%
-18086000
-0.3%
-18038000
-0.0%
-18037000
+14.4%
-21059000
EPS (Basic)
$-0.52
-52.9%
$-0.34
+0.0%
$-0.34
+0.0%
$-0.34
+15.0%
$-0.40
EPS (Diluted)
$-0.52
-52.9%
$-0.34
+0.0%
$-0.34
+0.0%
$-0.34
+15.0%
$-0.40
Shares (Diluted)
66.2M
+24.1%
53.4M
+0.1%
53.3M
+0.2%
53.2M
+0.4%
53.0M
PMV Pharmaceuticals (PMVP) — Financials